An observational study in Autism Spectrum Disorders, sponsored by Antonella Costantino. Recruiting at 3 sites in Italy. Open to participants aged 0 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-02-20.
Sponsored by Antonella Costantino · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies in Autism Spectrum Disorder with a site in Italy — 48 open to participants now, 55 under way, 1 of them phase 3. Autism Spectrum Disorder · Italy.
Among the 90 studies in Autism Spectrum Disorder with a site in Italy, this one is the 2nd largest by planned enrollment of the 27 observational ones that give a count, is one of 6 that started in 2025, is one of 27 observational ones, reaches primary completion later than 41 of the 54 other live ones, and was the 76th registered.
1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.
Browse Autism Spectrum Disorder studies →48 of the 90 studies in Autism Spectrum Disorder with a site in Italy are open now. Recruiting first, the newest first:
University of Milan · Sites in Italy
Ages 6–14
IRCCS San Raffaele Roma · Sites in Italy
Ages 2–18 · Healthy volunteers
Istituto per la Ricerca e l'Innovazione Biomedica · Sites in Italy
Ages 6–13
Istituto per la Ricerca e l'Innovazione Biomedica · Sites in Italy
Ages 4–12 · Healthy volunteers
IRCCS Eugenio Medea · Sites in Italy
Ages 18 mo–60 mo
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.
This study: 0 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 6
First in 2012; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 103 across 323 observational studies indexed under Autism Spectrum Disorder.
Median enrollment 50 across the 63 interventional studies, 100 across the 27 observational. Of the 31 that completed or were terminated, 8 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 90 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Antonella Costantino as lead sponsor.
Antonella Costantino has 1 study filed under Autism Spectrum Disorder — fewer than ten, so there is no comparison to draw.
11 of the studies in Autism Spectrum Disorder with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06514573Istituto Superiore di SanitàButyrate Supplementation in Children With Autism Spectrum Disorder (ASD) and Functional Gastrointestinal Disorders | 2026-11 |
| NCT07519369IRCCS San Raffaele RomaMonitoring Daily Mobility in Children With Autism | 2026-12 |
| NCT07389720IRCCS Eugenio MedeaCharacterization of (A)Typical Sensorimotor Pathways in Individuals With Autism | 2026-12 |
| NCT07470138IRCCS Eugenio MedeaSleep Disturbance in Subjects With Autism Spectrum Disorders (ASD) in Preschool Age (18-60 Months) | 2026-12-15 |
| NCT07643649Istituto per la Ricerca e l'Innovazione BiomedicaCognitive Training in Virtual Reality for Autism | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 90 studies in Autism Spectrum Disorder with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
ASD is a very complex and lifelong disorder. Patients' functioning is influenced by multiple factors, including treatments, inclusion and life contexts. Nonetheless, outcome measures are still point-specific and highly fragmented, rarely considering global or multidimensional functioning, development or long-term modifications, especially in the real world. The present study considers ongoing real-life treatments in three different NHS settings, in line with the Italian Guidelines. Two age classes will be considered, 0-5 and 6-11, adding new outcome tools pre-post intervention to those already used, to evaluate quality of life, global functioning, multidimensional needs and strengths and shared decision making. Correlations between the different outcome tools will be explored, and possible clusters will be investigated. Acceptability of the outcome tools for the operators, patients and families, as well as usefulness and sustainability in daily practice, will also be evaluated.
Children diagnosed with ASD enrolled in one of the intervention programs in line with the national guidelines, within the partner institutions or other NPIA/rehabilitation services for developmental age of the Lombardy Region are eligible. The overall expected sample is 400 male and female children, under 12 years of age, 200 children aged 0-5 years at T0 and 200 children aged 6-11 years at T0.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients will be enrolled in ongoing treatments in the real context as long as they are in line with the national guidelines for autism, in at least three different national health facilities (SSN) in Lombardy, to represent the variability of the possible organizations of services and interventions, adding new outcome tools.
Other: DD-CGAS (Wagner et al. 2007) · Other: Pediatric Quality of Life Inventory (PedsQL). · Other: Child and Adolescent Needs and Strengths (CANS) (Lyons 2022)
The DD-CGAS is a clinician-completed scale that provides a global rating of the child's functioning. The score refers to the subject's typical functioning during a specified period of time, usually the week prior to the assessment. It is a global assessment based on all available sources of information and all domains of functioning, including self-sufficiency, communication, social behavior, and academic/school functioning. The score should not be influenced by the specific diagnosis, the perceived cause of dysfunction (e.g., cognitive or physical limitation, environmental constraints, behavioral disturbance), or the type and severity of symptoms. The DD-CGAS is a dimensional scale with scores ranging from 1 to 100, with 1 representing the greatest impairment in functioning and 100 representing the best functioning. Each decile (e.g., 1-10, 11-20) has a specific description. The instrument has excellent replicability between raters and temporal stability.
The PedsQL is designed for children and adolescents between the ages of 2 and 18 years and takes approximately 5 minutes to complete. It is administered as a self-report instrument or via proxy interview. The proxy interview version corresponds to the age of the child (e.g., 2-4 years, 5-7 years, 8-12 years, and 13-18 years). The PedsQL consists of 23 items that assess 4 broad scales, including: physical functioning, emotional functioning, social functioning, and academic functioning. Items are rated using a 5-point Likert scale (0 = never; 4 = almost always), with the total score calculated as the sum of all items considered. PedsQL item scores are inverted and linearly transformed to a 0 to 100 scale, with higher scores indicating a better perception of health-related quality of life. It is important to note that the PedsQL has been validated in children with autism, including parents of children with autism (Vasilopoulou et al. 2016; Perry, N. et al. 2024).
The Child and Adolescent Needs and Strengths scale (CANS) (Lyons 2022) is an open source tool widely used to assess the needs and strengths of children, adolescents, and their families, in clinical, educational and social services settings. It is organized into multiple domains that cover various aspects of a child's life. Common domains include life functioning, behavioral/emotional needs, risk behaviors, strengths, caregiver needs and strengths. Additional modules as trauma can be used.The tool uses a scoring system that reflects the level of need or strength in each area. Typically, needs are rated on a scale from 0 to 3, where 0: No evidence of problems; 1: Watchful waiting, preventive action needed; 2: Action or intervention is required; 3: Immediate or intensive action required. Strengths are rated similarly, with higher scores reflecting greater need for action to support the development of each specific strength.
Specific clusters of CANS items that differentiate the profiles of needs and strengths of users at T0.
The primary objective of the study is to identify specific clusters of CANS items that differentiate the profiles of needs and strengths of users at T0.
Time frame: From March 2025 to August 2026
Correlations between CANS assessment and participants' global functioning (DD-CGAS)
The outcome measure TAI measured with CANS and expressed as the sum of the actionable items (see section "Groups and Intervention") will be correlated will be correlated with outcome measure quality of life, measured with DD-CGAS expressed as 1-100 score con 1 che rappresenta la maggiore compromissione del funzionamento e 100 il miglior funzionamento
Time frame: From March 2025 to August 2026
Correlations between CANS assessment and participants' quality of life (PEDSQL)
The outcome measure TAI measured with CANS and expressed as the sum of the actionable items (see section "Groups and Intervention") will be correlated will be correlated with outcome measure quality of life, measured with DD-CGAS expressed as 0-100 score with higher scores on the PedsQL indicating better perceptions of health-related quality of life.
Time frame: From March 2025 to August 2026
Evaluation of changes in children's needs over time based on CANS actionable items.
Differences between T0 and T1 TAI measeured with CANS and expressed as the sum of the actionable items (see section "Groups and Interventions") will be evaluated using a paired sample t test.
Time frame: march 2025 to august 2026
Evaluation of changes in children's Quality of Life over time.
Differences between T0 and T1 PedsQL scores (range 0-100, where 0 represents the lowest quality of life and 100 represents the highest quality of life ) will be evaluated using a paired sample t test.
Time frame: from march 2025 to august 2026
Evaluation of changes in children's global functioning
DESCRIPTION Differences between T0 and T1 DD-CGAS scores (range 1-100, where 1 represents the lowest level of global functioning and 100 represents the highest level of global functioning) will be evaluated using a paired sample t test.
Time frame: from march 2025 to august 2026
Plan to share: No
Started Mar 2025 (actual). Primary completion is estimated for Oct 2026, 19 months after the start.
Of 98 non-industry observational studies under Autism Spectrum Disorder, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 120. This study's planned 19 months is below that.
Counting every sponsor, half of 112 studies reached it within 40 months; a quarter within 26 and three quarters within 120.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.